Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.440
+0.170 (7.49%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Editas Medicine Revenue
Editas Medicine had revenue of $11.89M in the quarter ending June 30, 2026, with 232.31% growth. This brings the company's revenue in the last twelve months to $47.01M, up 20.83% year-over-year. In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth. That makes Editas Medicine the 28,364th largest company in the world by revenue and 3,830th in the United States.
Revenue (ttm)
$47.01M
Revenue Growth
+20.83%
P/S Ratio
7.97
Revenue / Employee
$540,287
Employees
87
Market Cap
374.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 116.93M |
| Fennec Pharmaceuticals | 59.22M |
| Prothena Corporation | 54.53M |
| vTv Therapeutics | 36.84M |
| Prelude Therapeutics | 22.42M |
| Capricor Therapeutics | 11.13M |
| Opus Genetics | 9.86M |
EDIT News
- 1 day ago - Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - GlobeNewsWire
- 7 days ago - Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light - TheFly
- 7 days ago - Editas Medicine upgraded to Overweight from Equal Weight at Wells Fargo - TheFly
- 7 days ago - Editas Medicine receives approval to initiate clinical trial of EDIT-401 - TheFly
- 7 days ago - Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia - GlobeNewsWire
- 22 days ago - Editas slips amid pressure on gene-editing sector after Anthropic update - TheFly
- 22 days ago - Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential - TheFly
- 22 days ago - Editas Medicine upgraded to Buy from Neutral at Guggenheim - TheFly